A tweetorial on our study (gastrojournal.org/article/S0…). But, first a case: Young female w/ a 1.9 cm incidental pancreatic cyst. No concerning features, but KRAS, TP53 and SMAD4 mutations on molecular testing. Surgical resection: #IPMN w/ a small #PancreaticCancer. #Pathology #GIPath

The House Appropriations Committee passed its version of the FY27 spending bill, including an increase of $110 million compared to the current year’s budget for @theNCI 👏🏽👏🏽 From @TheCancerLetter cancerletter.com/capitol-hil… The Senate will now take up its version of appropriations.

Papillary adenocarcinoma of head of pancreas, with metastases to common bile duct and lung @NEJM 1946 Case records of MGH. Probably one of the first descriptions of what we would now call as #PancreaticCancer arising in a main duct intraductal papillary mucinous neoplasm (IPMN).

Hopkins will provide $280M in mid-size and large grants to support faculty for 2 years (1) $160M for all life scientists (from basic to translation) (2) $120M for all science and engineering. This cannot replace federal funding, not even close, but it helps.

🤩 spatial panoramic in vivo CRISPR screen via Perturb-DBiT 🤩 Excited to share our collaborative work with @sidichen lab and many outstanding collaborators, now published in Nature Biotechnology! nature.com/articles/s41587-0…

PanCAN's Chief Scientific and Medical Officer, Dr. @ABerkenblit, shares, "I know that in the years to come, we'll look back on this year's #ASCO26 meeting as marking the beginning of a new era for patients with pancreatic cancer. As a long-standing American Society of Clinical Oncology (ASCO) member, it was a privilege this year to attend alongside my colleagues from Pancreatic Cancer Action Network, knowing the pivotal role PanCAN played to get us to this historic moment, and that the community is looking to PanCAN to help us all make good on the promise that RAS therapies hold for patients with pancreatic cancer. Unprecedented indeed are the Phase 3 data for #daraxonrasib, a RAS-targeted therapy developed by Revolution Medicines and presented by Dr. Brian Wolpin. These highly anticipated data were received with wild enthusiasm — a standing ovation! — from the ASCO community. Overall survival and progression-free survival were ~doubled, and overall response rate was ~tripled with daraxonrasib compared with chemotherapy in patients with previously treated metastatic pancreatic cancer, with all subgroups benefiting. Importantly, quality of life and pain were improved, so that patients not only live longer, but also feel better — just what we want from new therapies. Optimal management of side effects, including rash and mouth sores, is paramount to maximize the benefit — and PanCAN Patient Services is ready to embrace the educational needs!" Learn more about the additional data released on daraxonrasib and this significant advance for #pancreaticcancer treatment at 🔗 pcan.at/rjul9sza.

Important research shared by Dr. Diwakar Davar (@diwakardavar) at #ASCO26 on a PRAME-directed T-cell therapy for patients with advanced melanoma. The research showed meaningful responses in patients with limited treatment options, highlighting a promising approach for difficult-to-treat melanoma. @UPMCHillmanCC #ASCO26 #MoffittASCO26

Multi-omics approaches are unravelling the complex biological landscape of pancreatic #NETs Building on this collective effort, we have integrated this remarkable body of knowledge into a comprehensive overview rdcu.be/flQyn @PancPathologist @VolkanAdsay @Chris_Heaphy

Incredible #ASCO26 moment. Dr. Brian Wolpin, presenter of the daraxonrasib study, received a standing ovation DURING his talk after he stated the survival benefit for PDAC patients. It was sustained. Cheering. I have never see anything like it in the middle of a talk. $RVMD

Next up is the one and only @OncoThor discussing emerging targets in pancreatic NETs. #ASCO26

Presented at #ASCO26: Among patients with previously treated metastatic pancreatic ductal adenocarcinoma, the RAS(ON) inhibitor daraxonrasib led to significantly longer overall survival and progression-free survival than chemotherapy. Full phase 3 RASolute 302 trial results: nej.md/4nWaxvM @ASCO

A warm #ASCO26 welcome to daraxonrasib and RASolute-302 study in 2nd line metPDAC from $RVMD My story in the post below. Here are the OS curves you haven't seen yet.

Don’t typically see these kinds of headlines in #PancreaticCancer but today’s #ASCO26 plenary on @RevMedicines Daraxonrasib brings it. ‘Landmark’ pancreatic cancer drug keeps patients alive for twice as long By @Carolynyjohnson @washingtonpost washingtonpost.com/health/20…

The overall survival curves for Daraxonrasib in 2nd line advanced #PancreaticCancer leave no doubt how impactful this advance is for the field & for patients. Congratulations Brian Wolpin, @EileenMOReilly & @md_oberstein et al. A seminal #ASCO26 plenary! nejm.org/doi/full/10.1056/NE…

Join @AnwaarSaeed3 at #ASCO26 this morning for 2 posters-expansion study of spevatamig as mono/combo for GI cancers (Bd175) & @NSABPFoundation (EMPIRE)-study of cemiplimab mono/combo therapy in #colorectalcancer (Bd445b) @UPMCnews @PittHealthSci

Morning poster sessions underway at #ASCO26. @AnwaarSaeed3 on 2 studies on GI & #coloncancer - (bd 445b/Bd 175) Anushri Kulkarni on how diet affects immune therapy(Bd 269) -Dr Vince Reyes on IV vs subcutaneous immune therapy (Bd 595a). @UPMCnews @PittHealthSci @UPMCPhysicianEd

Ralph is an absolute gentleman - kind, thoughtful, gracious, and generous. Truly grateful for his trust and support! 💕

Ready for #ASCO26 with @UPMCHillmanCC & @PittHealthSci experts share new progress being made in #cancer research. See you there! hillmanresearch.upmc.edu/abo…

As @RalphHruban retires as Director of @JHUPath this fall, I wanted to thank him for his many years of mentorship and friendship. A couple of "aged" photos of the #GIPath team from 2001 and 2008. Fortunately, his #PancreaticCancer research will continue full speed! Thanks Ralph!

Great example of bench science to clinical trial! In 2019, Bradley Bernstein & @DrSarcoma identified that SDH1 deficient GISTs harbor loss of an "insulator" that leads to FGF4 oncogene expression. nature.com/articles/s41586-0… Today, the FGFR1 inhibitor trial: nature.com/articles/s41591-0…

Fibrosis at the crossroad of tissue homeostasis and cancer events.cancer.gov/dcb/cancer… Free @theNCI workshop that one can attend virtually (link above) Featuring talks by @MaraShermanLab @ednacukierman @rkalluriMDPhD @Pasca_Lab @megeblad @JHElisseeff @ZanivanLab @DeNardoLabWUSM